Doug Manion M.D., FRCP(C)
Doug is CEO of Kleo Pharmaceuticals. He has 20 years’ experience in drug development. He was the Senior Vice President, Head of Specialty Development and Head of Japan and China R&D at BMS until October 2016. He had leadership roles at BMS overseeing various therapeutic areas including virology, immunoscience, neurology, cardiology, metabolic diseases, genetically-defined diseases and fibrosis since joining in 2005. From 2001 to 2005, he was Vice President of Clinical Development and Medical Affairs for HIV/AIDS at GSK. He started his career at DuPont Pharmaceuticals in 1997. He is Board Certified in Internal Medicine and completed his Fellowship in Infectious Diseases in Ottawa Canada and a clinical and bench research fellowship at Massachusetts General Hospital and Harvard Medical School. Doug also serves on the Board of Directors of Celleron Therapeutics.
David A. Spiegel, M.D. PH.D.
David is the Chief Scientific Advisor and co-founder of Kleo Pharmaceuticals. He is a Professor of Chemistry and Pharmacology at Yale University where he heads the Spiegel Research Group. He has co-authored over 40 peer-reviewed publications and is an inventor with over a dozen patents, including those that underlie Kleo's ARM and SyAM platforms. He has been recognized with various awards and honors, including the NIH Director's New Innovators Award, the Ellison Medical Foundation New Scholar Award in Aging Research, the Bill and Melinda Gates Foundation Grand Challenges Explorations Award, an Alfred P. Sloan Foundation Fellowship, an Arthur C. Cope Early Career Scholars Award, and others.
Roy Prieb is the COO/CFO and co-founder of Kleo Pharmaceuticals. He is a technology entrepreneur with over 15 years experience in business strategy, development, and operations. Roy has helped launch, fund, and grow several digital media ventures including Saaspire, Kellogg Media Group, Qiosk.com, and JibJab.com. Earlier in his career, he was a consultant with The Boston Consulting Group. He received his B.A. from Harvard University and M.B.A. from Wharton Business School.